NewAmsterdam Pharma Company N.V.
NAMS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.53 | -0.06 | 0.14 | -0.02 |
| FCF Yield | -6.57% | -15.39% | 5.05% | -17.07% |
| EV / EBITDA | -6.85 | -3.26 | 11.68 | -2.73 |
| Quality | ||||
| ROIC | -23.26% | -61.55% | -0.80% | -61.57% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 0.00% |
| Cash Conversion Ratio | 0.66 | 0.80 | -0.47 | 0.71 |
| Growth | ||||
| Revenue 3-Year CAGR | -23.73% | – | – | -100.00% |
| Free Cash Flow Growth | -12.74% | -1,452.37% | 135.36% | -301.37% |
| Safety | ||||
| Net Debt / EBITDA | 3.19 | 1.92 | 20.93 | 1.46 |
| Interest Coverage | 0.00 | -26.91 | -12.39 | -85.10 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 170.67 | 48.73 | 0.00 | 0.00 |